08 Feb 2007 Johnson & Johnson Psoriasis Drug CNTO 1275 Posts Mixed Results In Phase 2 Trial
07 Feb 2007 ImClone Systems Opts-out of Development Agreement with UCB to Focus Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121B
06 Feb 2007 AstraZeneca Licenses Regeneron's Velocimmune(R) Technology For Discovering Human Monoclonal Antibodies
06 Feb 2007 Merck KGaA Seeks Approval for Erbitux for Colorectal Cancer in Japan
06 Feb 2007 UCB Licenses BioWa's POTELLIGENT(R) Technology for use in Antibody Research and Development
03 Feb 2007 Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis
02 Feb 2007 Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26
26 Jan 2007 Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
26 Jan 2007 Amgen's Fourth Quarter 2006 Revenue Increased 17% to $3.8 Billion; Full Year 2006 Revenue Increased 15% to $14.3 Billion
25 Jan 2007 Lucentis receives approval in the European Union - the first drug to improve vision in patients with wet AMD, a leading cause of blindness
25 Jan 2007 Kirin and Astellas Enter Into a Licensing Agreement on an Immunosuppressive Fully Human Monoclonal Antibody
25 Jan 2007 First Actemra multinational phase III trial demonstrates significant improvement in signs and symptoms of rheumatoid arthritis
24 Jan 2007 Medarex and Compugen Announce Therapeutic Antibody Co-Development Agreement
18 Jan 2007 XOMA and Schering-Plough Add New Programs to Antibody Collaboration
17 Jan 2007 Trubion Announces Completion of Enrollment and Dosing of Patients in Phase IIb Clinical Trial of TRU-015 for the Treatment of Rheumatoid Arthritis
17 Jan 2007 Oxford Biomedica Announces Publication Of Avian Transgenic Results In Leading U.S. Scientific Journal
17 Jan 2007 Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial
16 Jan 2007 4- Antibody AG Closes CHF 17 Million Series A Financing, Bringing the Total Series A Financing to CHF 23 Million ($ 18.5Million)
13 Jan 2007 BioInvent enters collaboration with Genentech to develop and commercialize BioInvent´s proprietary antibody for the potential treatment of cardiovascular diseases
12 Jan 2007 Immuno-Biological Laboratories Co., Ltd. and Intellect Neurosciences, Inc. Enter into Humanized Monoclonal Antibodies Development Agreement for the Treatment of Alzheimer's Disease
11 Jan 2007 Organon and the Academic Medical Center jointly develop novel treatment of rheumatoid arthritis
11 Jan 2007 ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
10 Jan 2007 BioWa and Medarex Announce Allowance of Investigational New Drug Application for Second-Generation Anti-CD30 Antibody (MDX-1401) Enhanced Using Potelligent(TM) Technology
09 Jan 2007 Ablynx and Boehringer Ingelheim sign $265 million research and licensing agreement to develop new Alzheimer's treatments
09 Jan 2007 Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up